¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"glucose tolerance factor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 2
¿µ¹® risk factor ÇÑ±Û À§ÇèÀÎÀÚ
¼³¸í   
  ±¹Á¦¹æ»ç¼±¹æÈ£À§¿øÈ¸(ICRP)°¡ 1977³â ±Ç°í¿¡¼­ ¹æ»ç¼±¹æÈ£ÀÇ ¸ñÀûÀ¸·Î Ã¤ÅÃÇÑ Áö¼ö·Î, ´ÜÀ§¼±·®(1 Sv)´ç È®·üÀû ¿µÇâÀÇ ¹ß»ýÈ®·üÀ» ÃßÁ¤ÇÏ¿© ³ªÅ¸³½ °ÍÀÌ´Ù. »ý½Ä¼± ¼±·®¿¡ ´ëÇÑ À¯ÀüÀû¿µÇâÀÇ ¹ß»ý·ü(4¡¿10£­3/Sv)À̳ª Àû»ö°ñ¼ö¼±·®¿¡ ´ëÇÑ ¹éÇ÷º´ ¹ß»ý·ü(2¡¿10£­3/Sv)µî ¿Ü¿¡ »À, ÇãÆÄ, °©»ó»ù, Á¥»ù, ±âŸ Á¶Á÷ÀÇ À§ÇèÁö¼ö¸¦ ÃøÁ¤ÇÏ¿©, È®·üÀû ¿µÇâÀÇ Àü½Å¿¡ À־ Ä¡»çÀ§ÇèÁö¼öÀÇ Çհ踦 16.5¡¿10£­3/Sv·Î ÇÏ¿´´Ù. ±×ÈÄ ICRP´Â 1990³â ±Ç°í¿¡¼­ ´ë»óÀÌ µÇ´Â Á¶Á÷°ú Àå±â¸¦ Ãß°¡Çϰí, ¼öÄ¡ °³Á¤À» Çϸ鼭 ¸íεµ °¢¸ñÀûÈ®·üÁö¼ö¶ó°íÇÏ¿´´Ù. ÀÌ ±Ç°í¿¡ ÀÇÇϸé, Ä¡»çÀû È®·üÀû ¿µÇâÀÇ È®·üÁö¼öÀÇ ÇÕ°è´Â, ÀϹÝÀο¡ ÀÖ¾î 60.0¡¿10£­3/SvÀÌ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • acquired tolerance
    ȹµæ³»¼º
  • adoptive tolerance
    ÀÔ¾ç¸é¿ªÇã¿ë
  • cross-tolerance
    ±³Â÷³»¼º
  • drug tolerance
    ¾à¹°³»¼º, ¾à¹°ÀúÇ×¼º
  • exercise tolerance test
    ¿îµ¿³»¼º°Ë»ç
  • high dose tolerance
    Ç׿ø°ú·®Çã¿ë
  • high zone tolerance
    Ç׿ø°ú·®Çã¿ë
  • immunologic tolerance
    ¸é¿ªÇã¿ë
  • low-dose tolerance
    Ç׿ø¼Ò·®Çã¿ë
  • low-zone tolerance
    Ç׿ø¼Ò·®Çã¿ë
  • maximum tolerance dose
    1. ÃÖ´ë³»¾à¿ë·®, ÃÖ´ë³»¾à·® 2. ÃÖ´ë°ßµõ¼±·®
  • median tolerance limit
    ¹Ý¼ö»ýÁ¸ÇѰè³óµµ
  • organ tolerance dose
    ±â°ü°ßµõ¼±·®
  • oxygen tolerance
    »ê¼Ò³»¼º
  • self-tolerance
    1. ÀÚ°¡°ü¿ë 2. ÀÚ°¡³»¼º
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • platelet-derived growth factor
    Ç÷¼ÒÆÇÀ¯·¡¼ºÀåÀÎÀÚ, Ç÷¼ÒÆÇ±â¿ø¼ºÀåÀÎÀÚ
  • precipitation factor
    ÃËÁø¿äÀÎ
  • predisposing factor
    ¼±Çà¿äÀÎ
  • prognostic factor
    ¿¹ÈÄÀÎÀÚ
  • psychological factor
    ½É¸®¿ä¼Ò
  • relaxing factor
    ÀÌ¿ÏÀÎÀÚ
  • resistance factor
    ³»¼ºÀÎÀÚ, °ßµõÀÎÀÚ
  • rheumatoid factor
    ·ù¸¶Æ¼½ºÀÎÀÚ
  • risk factor
    À§ÇèÀÎÀÚ
  • transforming growth factor
    Àüȯ¼ºÀåÀÎÀÚ
  • vascular endothelial growth factor
    Ç÷°ü³»ÇǼºÀåÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • acceleration tolerance
    °¡¼Ó³»¼º
  • acquired tolerance
    ȹµæÇã¿ë, ÈÄõ³»¼º, ÈÄõÇã¿ë, ȹµæ°ü¿ë
  • adoptive tolerance
    ÀÔ¾ç¸é¿ªÇã¿ë
  • cross-tolerance
    ±³Â÷³»¼º
  • carbohydrate tolerance test
    ź¼öÈ­¹°³»¼º½ÃÇè
  • cross tolerance
    ±³Â÷³»¼º
  • drug tolerance
    ¾à¹°³»¼º, ¾à¹°ÀúÇ×¼º
  • maximum tolerance dose
    ÃÖ´ë³»¾à¿ë·®, ÃÖ´ë³»¾à·®, ÃÖ´ë°ßµõ¼±·®
  • organ tolerance dose
    ±â°ü°ßµõ¼±·®
  • tolerance dose
    °ßµõ¼±·®
  • exercise tolerance test
    ¿îµ¿³»¼º°Ë»ç
  • heat tolerance
    ³»¿­¼º
  • heparin tolerance test
    ÇìÆÄ¸°³»¼º°Ë»ç
  • high-dose tolerance
    Ç׿ø°ú·®Çã¿ë
  • high-zone tolerance
    Ç׿ø°ú·®Çã¿ë
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • galactose tolerance test
    °¥¶ôÅ佺ºÎÇÏ ½ÃÇè.
  • genetic tolerance dose
    À¯ÀüÀû ³»·®(¡­Ò±åÖ).
  • heat tolerance
    ³»¿­¼º(Ò±æðàõ).
  • heat tolerance
    ³»¿­¼º(ËÀËçËÛ).
  • heparin protamin tolerance test
    ÇìÆÄ¸° ÇÁ·ÎŸ¹Î ³»¼º½ÃÇè(¡­Ò±àõãËúÐ).
  • heparin protamin tolerance test
    ÇìÆÄ¸° ÇÁ·ÎŸ¹Î ³»¼º½ÃÇè(?ËÀËÛËàÌ´).
  • heparin tolerance test
    ÇìÆÄ¸°³»¼º½ÃÇè.
  • high dose tolerance
    °ú·®°ü¿ë
  • high-zone tolerance
    °í¿ª°ü¿ë, Ç׿ø°ú·®°ü¿ë
  • immune tolerance
    ¸é¿ª°ü¿ë
  • immunologic tolerance
    ¸é¿ª°ü¿ë(Øóæ¹Î°é»)
  • immunologic tolerance
    ¸é¿ª°ü¿ë(¡­Î°é»)
  • immunological tolerance
    ¸é¿ª³»¼º.
  • induction, tolerance
    °ü¿ëÀ¯¹ß (¸é¿ª)
  • infectious tolerance
    Àü´Þ¼º ¸é¿ª°ü¿ë
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • glucose
    ±Û·çÄÚ½º, Æ÷µµ´ç.
  • glucose
    Æ÷µµ´ç
  • glucose
    Æ÷µµ´ç
  • glucose 1 phosphate
    ±Û·çÄÚ¿À½º-1-Àλê.
  • glucose 3 phosphatase =G-3-P
    ±Û·çÄÚ¿À½º-3-Æ÷½ºÆÄŸÁ¦.
  • glucose 6 phosphatase =G-6-P
    ±Û·çÄÚ¿À½º-6-Æ÷½ºÆÄŸÁ¦.
  • glucose 6 phosphatase deficiency hepa
    ±Û·çÄÚ¿À½º-6 -ÀÎ»ê °áÇ̰£½ÅÇü´ç
  • glucose 6 phosphate
    ±Û·çÄÚ¿À½º-6-Àλê.
  • glucose 6 phosphate dehydrogenase =G 6 PD
    ±Û·çÄÚ¿À½º 6Àλê Å»¼ö ¼ÒÈ¿¼Ò, ±Û·çÄÚ¿À½º-6-ÀÎ»ê µ¥È÷µå·Î°Ô³ªÁ¦.
  • glucose 6 phosphate dehydrogenase def
    ±Û·çÄÚ¿À½º-6-Àλê Å»¼ö¼Ò È¿¼Ò°á
  • glucose dehydrogenase
    ±Û·çÄÚ¿À½ºÅ»¼ö¼ÒÈ¿¼Ò, ±Û·çÄÚ¿À½ºµ¥È÷µå·Î°Ô³ªÁ¦.
  • glucose effect
    Æ÷µµ´çÈ¿°ú
  • glucose equivalent
    ±Û·çÄÚ¿À½º´ç·®.
  • glucose fermenter
    Æ÷µµ´ç¹ßÈ¿¼Ò
  • glucose fluctuation
    Æ÷µµ´çº¯µ¿
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • glucose
    ±Û·çÄÚ½º
  • glucose-alanine cycle
    ±Û·çÄÚ½º-¾Ë¶ó´Ñ ȸ·Î(üÞÖØ)
  • glucose effect
    ±Û·çÄÚ½º È¿°ú(üùÍý)
  • glucose electrode
    ±Û·çÄÚ½º Àü±Ø(ï³Ð¿)
  • glucose-6-phosphatase
    ±Û·çÄÚ½º-6-Æ÷½ºÆÄÅ×À̽º
  • glucose-6-phosphate
    ±Û·çÄÚ½º-6-Àλê(×òß«)
  • glucose-6-phosphate dehydrogenase
    ±Û·çÄÚ½º-6-Àλê(×òß«) µðÇÏÀ̵å·ÎÀú³×À̽º
  • glucose-6-phosphate dehydrogenase deficiency
    ±Û·çÄÚ½º-6-Àλê(×òß«) µðÇÏÀ̵å·ÎÀú³×À̽º °áÇÌ(ÌÀ
  • glucose-regulated protein
    ±Û·çÄÚ½º-Á¶Àý (ðàï½) ´Ü¹éÁú(Ó±ÛÜòõ)
  • glucose repression
    ±Û·çÄÚ½º ¾ïÁ¦(åäð¤)
  • UDP-glucose
    UDP-±Û·çÄÚ½º
  • uridine diphosphate glucose
    À¯¸®µò ÀÌÀλê(ì£×òß«) ±Û·çÄÚ½º
  • acetate-replacing factor
    ¾Æ¼¼Æ®»ê(ß«)ġȯ ÀÎÀÚ(öÇüµì×í­)
  • achromotrichia factor
    ¸ð¹ß»ö¼Ò°áÇÌÀÎÀÚ (Ù¾Û¥ßäáÈÌÀù¹ì×í­)
  • angiogenic factor
    Ç÷°üÇü¼ºÀÎÀÚ(úìηû¡à÷ì×í­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
PAF paroxysmal atrial fibrillation; peroxisomal assembly factor; phosphodiesterase-activating factor; pl...
SF Sabin-Feldman [test]; safety factor; salt-free; scarlet fever; screen film; seminal fluid; serosal f...
TF free thyroxine; tactile fremitus; tail flick [reflex]; temperature factor; testicular feminization; ...
AITT arginine insulin tolerance test; augmented insulin tolerance test
ATT arginine tolerance test; aspirin tolerance time
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
IVGTT I.v. glucose tolerance tests
IGT Impaired Glucose Tolerance
IVGTT Intravenous Glucose Tolerance Test
NGT Normal glucose tolerance
OGTT Oral Glucose Tolerance Test
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • individual tolerance
    °³Àκ° ³»¼º
    ºñÁ¤»óÀûÀ¸·Î ´ë·®ÀÇ ¾à¹°¿¡ ´ëÇÏ¿© µ¶¿µÇâÀ» ¹ÞÁö ¾Ê°í °ßµð¸ç ¶ÇÇÑ ÀÏÁ¤·®ÀÇ ¾à¹°ÀÇ Áö¼ÓÀûÀÎ »ç¿ë¿¡ ´ëÇØ¼­ È¿°úÀÇ °¨¼Ò¸¦ ³ªÅ¸³»´Â ´É·Â.
  • lactose tolerance test
    ¶ôÅä¿À½º ³»¼º ½ÃÇè
  • maximum tolerance dose
    ÃÖ´ë ³»¿ë·®, ÃÖ´ë °ßµõ ¼±·®
  • median tolerance limit
    ¹Ý¼ö »ýÁ¸ ÇÑ°è ³óµµ
  • organ tolerance dose
    ±â°ü Çã¿ë·®, Àå±â Çã¿ë·®
  • pain tolerance
    µ¿Åë ³»¼º, ÅëÁõ ³»¼º
    ÂüÀ» ¼ö ÀÖ´Â ÅëÁõÀÇ °¡Àå Å« ¼öÁØ.
  • pharmacodynamic tolerance
    ¾à¿ªÇÐÀû ³»¼º
  • poison tolerance
    µ¶¹° ³»¼º
    Áö¼ÓÀûÀÎ µ¶¼º ¹°Áú¿¡ ÀÇÇØ »ýü°¡ ±× µ¶¼º ¹°Áú¿¡ ÀúÇ×¼ºÀ» ³ªÅ¸³»´Â °Í.
  • tolerance
    ³»¾à¼º, ³»¼º, ³»¿ë·Â, Çã¿ë, °ü¿ë
    1. º¸Åë ¾à¹°À̳ª µ¶¹°ÀÇ ¸¹Àº »ç¿ë·®À» °ßµð¾î ³¾ ¼ö ÀÖ´Â ´É·Â. 2. ÈÄõÀûÀ¸·Î ȹµæµÈ ¾à¹° ³»¼º. ¹Ýº¹ÀûÀÎ µ¿·®ÀÇ »ç¿ë·®¿¡ ´ëÇÑ ¹ÝÀÀ¼ºÀÇ °¨¼Ò ȤÀº °°Àº ¹ÝÀÀÀ» ¾ò±â À§Çؼ­ Áõ°¡µÈ »ç¿ë·®À» ¿ä±¸ÇÏ´Â °Í.
  • tolerance span
    Àγ» ±â°£
  • tolerance to antimicrobial
    Ç×±ÕÁ¦ ³»¼º
  • tolerance to high altitude
    °í¼Ò ³»¼º
  • absorbed dose conversion factor
    Èí¼ö¼±·® º¯È¯ °è¼ö
  • accessory food factor
    ¿µ¾ç º¸Á¶ ÀÎÀÚ
    F.G Ho
  • air kerma calibration factor
    °ø±â Ä¿¸¶ ÃøÁ¤ °è¼ö, ´«±Ý ¸ÂÃã °è¼ö
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
species tolerance The insensitivity to a particular drug exhibited by a particular species.
(05 Mar 2000)
split tolerance Modification of an immune response to an antigen after prior exposure to that antigen.
Synonym: split tolerance.
(05 Mar 2000)
nonresponder tolerance Lack of immune response to antigen. Theories of tolerance induction include clonal deletion and clonal anergy. In clonal deletion, the actual clone of cells is eliminated whereas in clonal anergy the cells are present but nonfunctional.
Synonym: immunological tolerance, immunotolerance, nonresponder tolerance.
(05 Mar 2000)
drug tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from drug resistance wherein a human, animal, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug.
(12 Dec 1998)
immune tolerance The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (foetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc.
(12 Dec 1998)
immunological tolerance <immunology> Specific unresponsiveness to antigen. Self tolerance is a process occurring normally early in life due to suppression of self reactive lymphocyte clones.
Tolerance to foreign antigens can be induced in adult life by exposure to antigens under conditions in which specific clones are suppressed. Note that tolerance is not the same as immunological unresponsiveness, since the latter may be very non-specific as in immunodeficiency states.
(18 Nov 1997)
immunologic high dose tolerance Induction of tolerance by exposure to large amounts of protein antigens.
(05 Mar 2000)
immunologic tolerance Lack of immune response to antigen. Theories of tolerance induction include clonal deletion and clonal anergy. In clonal deletion, the actual clone of cells is eliminated whereas in clonal anergy the cells are present but nonfunctional.
Synonym: immunological tolerance, immunotolerance, nonresponder tolerance.
(05 Mar 2000)
individual tolerance Tolerance to a drug that the person has never received before.
(05 Mar 2000)
oral lactose tolerance test A test for lactose deficiency; the plasma glucose response to an oral lactose load is measured as in the (oral) glucose tolerance test.
(05 Mar 2000)
tolerance 1. The ability to endure unusually large doses of a drug or toxin.
2. Acquired drug tolerance, a decreasing response to repeated constant doses of a drug or the need for increasing doses to maintain a constant response.
Origin: L. Tolerantia
(18 Nov 1997)
tolerance dose The largest dose of a remedy that can be accepted without the production of injurious symptoms.
(05 Mar 2000)
exercise tolerance The exercise capacity of an individual as measured by endurance (maximal exercise duration and/or maximal attained work load) during an exercise test.
(12 Dec 1998)
frustration tolerance The level of an individual's ability to withstand frustration without developing inadequate modes of response, such as "going to pieces" emotionally.
(05 Mar 2000)
activated glucose A nucleoside diphosphoglucose such as UDP glucose.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • intrinsic factor
    (»ýÈ­)³»À缺ÀÎÀÚ
  • nerve growth factor
    (»ý¸®)½Å°æ ¼ºÀåÀÎÀÚ(Áö°¢(±³°¨)½Å°æ¼¼Æ÷ÀÇ ¼ºÀåÀ» ÀÚ±ØÇÏ´Â ´Ü¹éÁú)
  • noise factor(figure)
    (ÁõÆø±â¿¡¼­ÀÇ)ÀâÀ½Áö¼ö
  • pp factor
    Ç× Æç¶ó±×¶ó ÀÎÀÚ(Æç¶ó±×¶ó ¿¹¹æ¿¡ ¾²´Â ´ÏÄÚÆ¾»ê,´ÏÄÚÆ¾»ê¸¶À̵å)
  • prime factor
    ¼ÒÀμö
  • releasing factor
    È£¸£¸ó ¹æÃâÀÎÀÚ
  • rheumatoid factor
    ·ù¸ÓƼÁòÀÎÀÚ(¸¸¼º °üÀý ·ù¸ÓƼÁò ȯÀÚÀÇ ÀÚ±â Ç×ü)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á